Having trouble accessing articles? Reset your cache.

Bardoxolone data set Reata up to advance second compound toward registration

Weeks after regaining rights to cardiorenal compounds from AbbVie, Reata has reported its second pivotal trial success of the quarter, paving the way for global marketing applications for its two most advanced compounds as it awaits registrational data in follow-on indications.

On Tuesday, Reata Pharmaceuticals Inc. (NASDAQ:RETA) said bardoxolone, its first-generation NFE2L2 activator, met the primary endpoint of improving estimated glomerular filtration rate (eGFR) in the

Read the full 667 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE